Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

anti-CD137 monoclonal antibody

Known as: Anti-4-1BB Monoclonal Antibody, Immunoglobulin G4, Anti-(Human Receptor 4-1BB) (Human Gamma-Chain), Disulfide with Human Kappa-Chain, Dimer, URELUMAB 
A fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Anti-CD137… Expand
National Institutes of Health

Related topics

Related topics

6 relations
Antibody-Dependent Cellular CytotoxicityB-LymphocytesBMS-663513Cytotoxic T-Lymphocytes
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies.
4-1BB (CD137, tumor necrosis factor receptor superfamily 9) is an inducible costimulatory receptor expressed on activated T and… Expand
Is this relevant?
2018
2018
Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab
4-1BB (CD137, TNFRSF9) is an inducible costimulatory receptor expressed on activated T cells. Clinical trials of two agonist… Expand
Is this relevant?
2017
2017
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes
CD137(4-1BB) ligation with agonist monoclonal antibodies used in immunotherapy induces long-term sequence-specific CpG DNA… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
Purpose: Urelumab is an agonist antibody to CD137 with potential application as an immuno-oncology therapeutic. Data were… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2016
Highly Cited
2016
CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer
Purpose: Cetuximab, an EGFR-specific antibody (mAb), modestly improves clinical outcome in patients with head and neck cancer… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2-/-IL2Rγnull Immunodeficient Mice.
A current pressing need in cancer immunology is the development of preclinical model systems that are immunocompetent for the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
Modulation of the immune system by targeting coinhibitory and costimulatory receptors has become a promising new approach of… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
Recent investigations of the tumor microenvironment have shown that many tumors are infiltrated by inflammatory and lymphocytic… Expand
  • table 1
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion.
Despite the success of passive immunotherapy with monoclonal antibodies (mAbs), many lymphoma patients eventually relapse… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma
Purpose: Eradication of post-treatment residual myeloma cells is needed to prevent relapses, and immunostimulatory monoclonal… Expand
  • figure 2
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE